.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,114,120

« Back to Dashboard

Details for Patent: 6,114,120

Title: Systematic evolution of ligands by exponential enrichment: tissue selex
Abstract:A new class of nucleic acid compounds, referred to as nucleic acid ligands, have been shown to exist that have a specific binding affinity for three dimensional molecular targets, including cell surface macromolecules. The nucleic acid ligands are identified by the method of the invention referred to as the Systematic Evolution of Ligands by EXponential enrichment (SELEX), wherein a candidate mixture of nucleic acids are iteratively enriched and the high affinity nucleic acids are amplified for further partitioning. The high affinity nucleic acid ligands are useful in capturing target cells.
Inventor(s): Jensen; Kirk B (New York, NY), Chen; Hang (San Francisco, CA), Morris; Kevin N. (Goldegg, AT), Stephens; Andrew (Boulder, CO), Gold; Larry (Boulder, CO)
Assignee: NeXstar Pharmaceuticals, Inc. (Boulder, CO)
Filing Date:Oct 28, 1997
Application Number:08/945,909
Claims:1. A nucleic acid ligand to a cell target macromolecule identified according to the method comprising:

a) preparing a candidate mixture of nucleic acid sequences;

b) contacting said candidate mixture of nucleic acids with said cell, wherein nucleic acids having an increased affinity to the cell macromolecule relative to the candidate mixture may be partitioned from the remainder of the candidate mixture;

c) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture; and

d) optionally amplifying the increased affinity nucleic acids to yield a mixture of nucleic acids enriched for nucleic acid sequences with relatively higher affinity and specificity for binding to said cell,

whereby said nucleic acid ligand to said macromolecule may be identified.

2. A purified and isolated non-naturally occuring nucleic acid ligand to a cell macromolecule.

3. The purified nucleic acid ligand of claim 2 which is a non-naturally occurring nucleic acid ligand having a specific binding affinity for the cell target macromolecule, said macromolecule being a three dimensional chemical structure other than a polynucleotide that binds to said nucleic acid ligand through a mechanism which predominantly depends on Watson/Crick base pairing or triple helix binding, wherein said nucleic acid ligand is not a nucleic acid having the known physiological function of being bound by the target molecule.

4. The nucleic acid ligand of claim 2 which is a deoxyribonucleic acid ligand.

5. The nucleic acid ligand of claim 2 which is a ribonucleic acid ligand.

6. A method of purifying macromolecule component of a cell comprising:

a) identifying a nucleic acid ligand to said macromolecule according to the method comprising:

i) preparing a candidate mixture of nucleic acid sequences;

ii) contacting said candidate mixture of nucleic acids with said cell, wherein nucleic acids having an increased affinity to the cell macromolecule relative to the candidate mixture may be partitioned from the remainder of the candidate mixture;

iii) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture; and

iv) optionally amplifying the increased affinity nucleic acids to yield a mixture of nucleic acids enriched for nucleic acid sequences with relatively higher affinity and specificity for binding to said cell

whereby said nucleic acid ligand to said macromolecule may be identified;

b) separating said macromolecule component of said cell away from the remainder of said cell on the basis of affinity between said cell macromolecule and said nucleic acid ligand; and

c) purifying said macromolecule.

7. The method of claim 6 wherein said macromolecule is selected from the group consisting of a protein, lipid and carbohydrate.

8. A purified macromolecule identified according to the method of claim 6.

9. The purified macromolecule of claim 8 which is selected from the group consisting of a protein, lipid and carbohydrate.

10. The purified macromolecule of claim 9 which is a tumor associated antigen.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc